within Pharmacolibrary.Drugs.ATC.L;

model L01FF03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0036166666666666665,
    adminDuration  = 600,
    adminMass      = 1.5,
    adminCount     = 1,
    Vd             = 0.0056,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Durvalumab is a human monoclonal antibody that blocks programmed death-ligand 1 (PD-L1), thereby enhancing T-cell-mediated immune response against tumor cells. It is primarily used for the treatment of locally advanced or metastatic urothelial carcinoma and non-small cell lung cancer, and is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients (including non-small cell lung cancer, urothelial carcinoma). Parameters reported for intravenous administration in adults.</p><h4>References</h4><ol><li><p>Davar, D, et al., &amp; Zamarin, D (2024). Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. <i>Journal for immunotherapy of cancer</i> 12(11) –. DOI:<a href=&quot;https://doi.org/10.1136/jitc-2024-009336&quot;>10.1136/jitc-2024-009336</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39551600/&quot;>https://pubmed.ncbi.nlm.nih.gov/39551600</a></p></li><li><p>O&#x27;Hara, MH, et al., &amp; Wang-Gillam, A (2020). Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. <i>Journal of pancreatic cancer</i> 6(1) 21–31. DOI:<a href=&quot;https://doi.org/10.1089/pancan.2019.0018&quot;>10.1089/pancan.2019.0018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32219196/&quot;>https://pubmed.ncbi.nlm.nih.gov/32219196</a></p></li><li><p>Patel, MR, et al., &amp; Hamilton, EP (2025). Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors. <i>Targeted oncology</i> 20(1) 127–138. DOI:<a href=&quot;https://doi.org/10.1007/s11523-024-01110-8&quot;>10.1007/s11523-024-01110-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39560862/&quot;>https://pubmed.ncbi.nlm.nih.gov/39560862</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FF03;
